Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Dec;68(6):1227–1231. doi: 10.1038/bjc.1993.509

Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

R García 1, J M Hernández 1, M D Caballero 1, M González 1, J Galende 1, M C del Cañizo 1, L Vázquez 1, J F San Miguel 1
PMCID: PMC1968658  PMID: 8260377

Abstract

The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH > 320 U ml-1, age > 45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase > 190 UI dl and ESR > 40 mm h. In addition, Hb < 12.5 gr dl-1 and abdominal disease were statistically relevant for CR while a poor performance score (ECOG > or = 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH > 320 U ml-1 had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses. According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and stage) a predictive model was established that allows the stratification of patients into two prognostic groups: one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the present study shows that LDH is one of the most important prognostic factors in HD.

Full text

PDF
1227

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson H., Jenkins J. P., Brigg D. J., Deakin D. P., Palmer M. K., Todd I. D., Crowther D. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. Clin Radiol. 1985 Sep;36(5):449–454. doi: 10.1016/s0009-9260(85)80183-5. [DOI] [PubMed] [Google Scholar]
  2. Bennett M. H., MacLennan K. A., Easterling M. J., Vaughan Hudson B., Jelliffe A. M., Vaughan Hudson G. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol. 1983 Sep;34(5):497–501. doi: 10.1016/s0009-9260(83)80148-2. [DOI] [PubMed] [Google Scholar]
  3. Bonadonna G., Santoro A., Viviani S., Valagussa P. Treatment strategies for Hodgkin's disease. Semin Hematol. 1988 Apr;25(2 Suppl 2):51–57. [PubMed] [Google Scholar]
  4. Canellos G. P. The second chance for advanced Hodgkin's disease. J Clin Oncol. 1992 Feb;10(2):175–177. doi: 10.1200/JCO.1992.10.2.175. [DOI] [PubMed] [Google Scholar]
  5. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  6. Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983 Feb;1(2):146–153. doi: 10.1200/JCO.1983.1.2.146. [DOI] [PubMed] [Google Scholar]
  7. Crnkovich M. J., Leopold K., Hoppe R. T., Mauch P. M. Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol. 1987 Jul;5(7):1041–1049. doi: 10.1200/JCO.1987.5.7.1041. [DOI] [PubMed] [Google Scholar]
  8. Danieu L., Wong G., Koziner B., Clarkson B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res. 1986 Oct;46(10):5372–5379. [PubMed] [Google Scholar]
  9. Desch C. E., Lasala M. R., Smith T. J., Hillner B. E. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol. 1992 Feb;10(2):200–209. doi: 10.1200/JCO.1992.10.2.200. [DOI] [PubMed] [Google Scholar]
  10. Gribben J. G., Linch D. C., Singer C. R., McMillan A. K., Jarrett M., Goldstone A. H. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989 Jan;73(1):340–344. [PubMed] [Google Scholar]
  11. Hoppe R. T., Cox R. S., Rosenberg S. A., Kaplan H. S. Prognostic factors in pathologic stage III Hodgkin's disease. Cancer Treat Rep. 1982 Apr;66(4):743–749. [PubMed] [Google Scholar]
  12. Jaffe H. S., Cadman E. C., Farber L. R., Bertino J. R. Pretreatment hematocrit as an independent prognostic variable in Hodgkin's disease. Blood. 1986 Aug;68(2):562–564. [PubMed] [Google Scholar]
  13. Jagannath S., Dicke K. A., Armitage J. O., Cabanillas F. F., Horwitz L. J., Vellekoop L., Zander A. R., Spitzer G. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 1986 Feb;104(2):163–168. doi: 10.7326/0003-4819-104-2-163. [DOI] [PubMed] [Google Scholar]
  14. Kaplan H. S. Hodgkin's disease: biology, treatment, prognosis. Blood. 1981 May;57(5):813–822. [PubMed] [Google Scholar]
  15. Leibenhaut M. H., Hoppe R. T., Varghese A., Rosenberg S. A. Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients. J Clin Oncol. 1987 Jul;5(7):1050–1055. doi: 10.1200/JCO.1987.5.7.1050. [DOI] [PubMed] [Google Scholar]
  16. Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosenberg S. A., Coltman C. A., Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov;7(11):1630–1636. doi: 10.1200/JCO.1989.7.11.1630. [DOI] [PubMed] [Google Scholar]
  17. Loeffler M., Pfreundschuh M., Hasenclever D., Hiller E., Gerhartz H., Wilmanns W., Rohloff R., Rühl U., Kühn G., Fuchs R. Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group. Blut. 1988 Jun;56(6):273–281. doi: 10.1007/BF00320290. [DOI] [PubMed] [Google Scholar]
  18. Longo D. L., Young R. C., Wesley M., Hubbard S. M., Duffey P. L., Jaffe E. S., DeVita V. T., Jr Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986 Sep;4(9):1295–1306. doi: 10.1200/JCO.1986.4.9.1295. [DOI] [PubMed] [Google Scholar]
  19. Pillai G. N., Hagemeister F. B., Velasquez W. S., Sullivan J. A., Johnston D. A., Butler J. J., Shullenberger C. C. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer. 1985 Feb 15;55(4):691–697. doi: 10.1002/1097-0142(19850215)55:4<691::aid-cncr2820550403>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  20. Prosnitz L. R., Farber L. R., Kapp D. S., Scott J., Bertino J. R., Fischer J. J., Cadman E. C. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol. 1988 Apr;6(4):603–612. doi: 10.1200/JCO.1988.6.4.603. [DOI] [PubMed] [Google Scholar]
  21. Schneider R. J., Seibert K., Passe S., Little C., Gee T., Lee B. J., 3rd, Miké V., Young C. W. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer. 1980 Jul 1;46(1):139–143. doi: 10.1002/1097-0142(19800701)46:1<139::aid-cncr2820460122>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  22. Specht L., Nissen N. I. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol. 1988 Oct;41(4):359–367. doi: 10.1111/j.1600-0609.1988.tb00210.x. [DOI] [PubMed] [Google Scholar]
  23. Specht L., Nissen N. I., Walbom-Jørgensen S. Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. Scand J Haematol. 1985 Aug;35(2):166–173. doi: 10.1111/j.1600-0609.1985.tb01566.x. [DOI] [PubMed] [Google Scholar]
  24. Straus D. J., Gaynor J. J., Myers J., Merke D. P., Caravelli J., Chapman D., Yahalom J., Clarkson B. D. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990 Jul;8(7):1173–1186. doi: 10.1200/JCO.1990.8.7.1173. [DOI] [PubMed] [Google Scholar]
  25. Tubiana M., Henry-Amar M., Burgers M. V., van der Werf-Messing B., Hayat M. Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. J Clin Oncol. 1984 Mar;2(3):194–200. doi: 10.1200/JCO.1984.2.3.194. [DOI] [PubMed] [Google Scholar]
  26. Tubiana M., Henry-Amar M., Carde P., Burgers J. M., Hayat M., Van der Schueren E., Noordijk E. M., Tanguy A., Meerwaldt J. H., Thomas J. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989 Jan;73(1):47–56. [PubMed] [Google Scholar]
  27. Urba W. J., Longo D. L. Hodgkin's disease. N Engl J Med. 1992 Mar 5;326(10):678–687. doi: 10.1056/NEJM199203053261006. [DOI] [PubMed] [Google Scholar]
  28. Villamor N., Reverter J. C., Martí J. M., Montserrat E., Rozman C. Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease. Eur J Haematol. 1991 Jan;46(1):38–41. doi: 10.1111/j.1600-0609.1991.tb00511.x. [DOI] [PubMed] [Google Scholar]
  29. Wedelin C., Björkholm M., Biberfeld P., Holm G., Johansson B., Mellstedt H. Prognostic factors in Hodgkin's disease with special reference to age. Cancer. 1984 Mar 1;53(5):1202–1208. doi: 10.1002/1097-0142(19840301)53:5<1202::aid-cncr2820530530>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  30. Yahalom J., Gulati S. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. Ann Oncol. 1991 Feb;2 (Suppl 2):67–71. doi: 10.1007/978-1-4899-7305-4_11. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES